Credit: UT Southwestern
One of the leading goals of cancer research is a drug that would target RAS mutations, the most common oncogene. Work by UT Southwestern researchers Zhiewei Zhou, left, and Dr. Kenneth Westover, has identified a potential tactic for attacking RAS-driven cancers.